PERINDOPRIL ERBUMINE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C19H32N2O5.C4H11N
Molecular Weight	441.6046
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)(C)N.CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC

InChI

InChIKey=IYNMDWMQHSMDDE-MHXJNQAMSA-N

InChI=1S/C19H32N2O5.C4H11N/c1-4-8-14(19(25)26-5-2)20-12(3)17(22)21-15-10-7-6-9-13(15)11-16(21)18(23)24;1-4(2,3)5/h12-16,20H,4-11H2,1-3H3,(H,23,24);5H2,1-3H3/t12-,13-,14-,15-,16-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	C19H32N2O5
Molecular Weight	368.4678
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	5 / 5
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	C4H11N
Molecular Weight	73.1368
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1457697http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020184s022lbl.pdfhttp://pubs.rsc.org/-/content/getauthorversionpdf/C3AY42056Fhttp://www.hmdb.ca/metabolites/HMDB60574
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/1718688

Perindoprilat is a metabolite of perindopril. Perindopril is a long-acting angiotensin converting enzyme (ACE) inhibitor and it is used to treat high blood pressure, heart failure or stable coronary artery disease. Perindopril is designed to allow oral administration as perindoprilat is poorly absorbed from the gastrointestinal tract.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Angiotensin-converting enzyme 94 Target ID: CHEMBL1808 Sources: http://www.hmdb.ca/metabolites/HMDB60574	Inhibitor 8504		1.05 nM [IC50]
Angiotensin-converting enzyme 94 Target ID: CHEMBL1808 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17716647	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Unknown 2596
Unknown 2596
Stable coronary artery disease 7 Sources: https://www.drugs.com/pro/perindopril.html	Primary	Approved 8583	ACEON Approved Use Perindopril erbumine tablets are indicated for treatment of patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction. Perindopril erbumine tablets can be used with conventional treatment for management of coronary artery disease, such as antiplatelet, antihypertensive or lipid-lowering therapy. Launch Date 1993
Hypertension 575 Sources: https://www.drugs.com/pro/perindopril.html	Primary	Approved 8583	ACEON Approved Use Perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. Perindopril erbumine tablets may be used alone or given with other classes of antihypertensives, especially thiazide diuretics. Launch Date 1993
Parkinson's disease 232 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10800878	Palliative	Not Provided 511	Unknown Approved Use Unknown
Unknown 2596

C_max

Value	Dose	Co-administered	Analyte	Population
83.83 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21650082	4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered:		PERINDOPRIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3.54 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21650082	4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered:		PERINDOPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
130 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21650082	4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered:		PERINDOPRIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
170.61 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21650082	4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered:		PERINDOPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.05 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21650082	4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered:		PERINDOPRIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
38.01 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21650082	4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered:		PERINDOPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
40% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21650082	4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered:		PERINDOPRIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
80% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21650082	4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered:		PERINDOPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Doses

Dose	Population	Adverse events
4 mg 1 times / day steady, oral Recommended Dose: 4 mg, 1 times / day Route: oral Route: steady Dose: 4 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/12076191/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/12076191/	Disc. AE: Cough... AEs leading to discontinuation/dose reduction: Cough (2.8%) Sources: https://pubmed.ncbi.nlm.nih.gov/12076191/

AEs

AE	Significance	Dose	Population
Cough	2.8% Disc. AE	4 mg 1 times / day steady, oral Recommended Dose: 4 mg, 1 times / day Route: oral Route: steady Dose: 4 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/12076191/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/12076191/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2J2 33	UGT 219 CYP 303	CYP 74

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
CYP 150	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/15449971/	no
CYP2J2 36	inhibitor 4027 Sources: https://www.sciencedirect.com/science/article/pii/S0009279719303631	no

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP 303	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/15449971/	no
UGT 219	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020184s023lbl.pdf#page=9 Page: 9.0	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:132041	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:132041
ChemicalBook	CB0240343	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0240343
eMolecules	36754394	https://www.emolecules.com/cgi-bin/more?vid=36754394
MolPort	MolPort-006-395-652	https://www.molport.com/shop/molecule-link/MolPort-006-395-652
ZINC	ZINC000004217270	http://zinc15.docking.org/substances/ZINC000004217270

PubMed

Title	Date	PubMed
Challenges for the prevention of primary and secondary stroke: the importance of lowering blood pressure and total cardiovascular risk.	2001	11822538
[Effects of angiotensin-converting enzyme inhibitors and cosaar on quality of life of patients with pulmonary tuberculosis and chronic heart failure].	2001	11767390
Interventions for deliberately altering blood pressure in acute stroke.	2001	11686949
[Hypotension followed the first dose of angiotensin-converting enzyme inhibitor in patients with heart failure (a multicenter clinical trial)].	2001	11642085
[Effects of perindopril and its combination with indapamide on risk stratification in patients with hypertension].	2001	11642074
[The comparison of clinical effectiveness of perindopril and acebutolol in the primary hypertension treatment].	2001	11603173
[Effects of perstarium on the systolic and diastolic functions of the myocardium in patients with chronic cardiac failure].	2001	11588778
Vasoactive peptides and procollagen propeptides in patients with hypertension in relation to cardiac hypertrophy and diastolic heart failure: design of the study and patient characteristics.	2001 Aug	11685903
Anglo-Scandinavian Cardiac Outcomes Trial: a brief history, rationale and outline protocol.	2001 Aug	11685901
Comparison of endothelial pleiotropic actions of angiotensin converting enzyme inhibitors and statins.	2001 Dec	11795271
Assessment of perindopril's efficacy on arterial distensibility in mild to moderate hypertension.	2001 Jul	11759959
Coversyl plus--when monotherapy is not enough.	2001 Jun-Jul	11710312
New benefits of blood pressure lowering treatments for millions of stroke sufferers.	2001 Jun-Jul	11710310
The EUROPA trial: design, baseline demography and status of the substudies.	2001 Mar	11669411
Clinical benefit of very-low-dose perindopril-indapamide combination in hypertension.	2001 Nov	11848262
Amelioration of arterial properties with a perindopril-indapamide very-low-dose combination.	2001 Nov	11848258
[Clinical study of the month. Secondary prevention of cerebrovascular accident with perindopril: the PROGRESS study].	2001 Nov	11789395
[Early prevention of experimental left ventricular hypertrophy in experimental hypertension and angiotensin II levels].	2001 Nov	11707239
Effect of angiotensin-converting enzyme inhibition on renal filtration surface area in hypertensive rats.	2001 Nov	11703601
Does ACE inhibition slow progression of glomerulopathy in patients with Type 2 diabetes mellitus?	2001 Nov	11703440
Angiotensin-converting enzyme gene insertion/deletion, not bradykinin B2 receptor -58T/C gene polymorphism, associated with angiotensin-converting enzyme inhibitor-related cough in Chinese female patients with non-insulin-dependent diabetes mellitus.	2001 Nov	11699055
Angiotensin-converting enzyme inhibition improves defective angiogenesis in the ischemic limb of spontaneously hypertensive rats.	2001 Nov	11684080
Effects of combined administration of ACE inhibitor and angiotensin II receptor antagonist are prevented by a high NaCl intake.	2001 Nov	11677376
A double-blind trial of perindopril and nitrendipine in incipient diabetic nephropathy.	2001 Oct	11806464
Increased absorption of zinc from alimentary tract in primary arterial hypertension.	2001 Oct	11694000
Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol.	2001 Oct	11641310
Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats.	2001 Oct	11584371
Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway.	2001 Oct 12	11597990
Safety profile of perindopril.	2001 Oct 4	11591359
Effects of perindopril on cardiovascular remodeling.	2001 Oct 4	11591358
Perindopril treatment for congestive heart failure.	2001 Oct 4	11591357
Dosage considerations with perindopril for systemic hypertension.	2001 Oct 4	11591356
Efficacy of perindopril in the treatment of systemic hypertension.	2001 Oct 4	11591355
Hypertension. Introduction.	2001 Oct 4	11591354
Dietary n-3 polyunsaturated fatty acids affect the development of renovascular hypertension in rats.	2001 Sep	11716352
Very-low-dose combination of perindopril and indapamide as a novel strategy in first-line management of hypertension.	2001 Sep	11713850
Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation.	2001 Sep	11596665
Effect of blood pressure reduction on abnormal left atrial appendage function in untreated systemic hypertensive patients with sinus rhythm.	2001 Sep	11570661
Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack.	2001 Sep 29	11589932
Blood-pressure lowering for the secondary prevention of stroke.	2001 Sep 29	11589927
Identification and determination of selected medicines reducing hypertension by densitometric and gas chromatographic methods.	2001 Sep-Oct	11876439
[Antihypertensive agents after cerebral stroke are more effective than expected].	2001 Sep-Oct	11845587
Detection of coronary microvascular disease by means of cardiac scintigraphy.	2002 Feb	11875588
Progress in secondary prevention of stroke with PROGRESS. The perindopril protection against recurrent stroke study.	2002 Feb	11790290
Long-term treatment with perindopril ameliorates dobutamine-induced myocardial ischemia in patients with coronary artery disease.	2002 Jan	11855668
Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats.	2002 Jan	11786082
The PROGRESS Trial: preventing strokes by lowering blood pressure in patients with cerebral ischemia. Emerging therapies: critique of an important advance.	2002 Jan	11779934
Comparison of perindopril versus captopril for treatment of acute myocardial infarction.	2002 Jan 15	11792333
Effects of low-dose and early versus late perindopril treatment on the progression of severe diabetic nephropathy in (mREN-2)27 rats.	2002 Mar	11856772
Combined therapy with indapamide and perindopril but not perindopril alone reduced the risk for recurrent stroke.	2002 Mar-Apr	11874276

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Unknown

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:05:08 GMT 2025` Edited by `admin` on `Mon Mar 31 18:05:08 GMT 2025`
Record UNII	1964X464OJ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PERINDOPRIL ERBUMINE

Official Name

English

PERINDOPRIL TERT-BUTYLAMINE

Preferred Name

English

PERINDOPRIL ERBUMINE [MART.]

Common Name

English

PERINDOPRIL TERT-BUTYLAMINE [EP MONOGRAPH]

Common Name

English

PERINDOPRIL ERBUMINE [USAN]

Common Name

English

PERINDOPRIL ERBUMINE [USP MONOGRAPH]

Common Name

English

Perindopril erbumine [WHO-DD]

Common Name

English

AMLESSA COMPONENT PERINDOPRIL ERBUMINE

Common Name

English

PERINDOPRIL T-BUTYLAMINE

Common Name

English

PERINDOPRIL ERBUMINE [ORANGE BOOK]

Common Name

English

S-9490-3

Code

English

ACEON

Brand Name

English

MCN-A-2833-109

Code

English

NSC-758929

Code

English

(2S,3aS,7aS)-1-[(S)-N-[(S)-1-Carboxybutyl]alanyl]hexahydro-2-indolinecarboxylic acid, 1-ethyl ester, compound with tert-butylamine (1:1)

Common Name

English

1H-INDOLE-2-CARBOXYLIC ACID, 1-(2-((1-(ETHOXYCARBONYL)BUTYL)AMINO)-1-OXOPROPYL)OCTAHYDRO-, (2S-(1(R*(R*)),2.ALPHA.,3A.BETA.,7A.BETA.))-, COMPD. WITH 2-METHYL-2-PROPANAMINE (1:1)

Common Name

English

PERINDOPRIL ERBUMINE [VANDF]

Common Name

English

PERINDOPRIL ERBUMINE [JAN]

Common Name

English

PERINDOPRIL ERBUMINE [USP-RS]

Common Name

English

PERINDOPRIL TERT-BUTYLAMINE [MI]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C247

Created by admin on Mon Mar 31 18:05:08 GMT 2025 , Edited by admin on Mon Mar 31 18:05:08 GMT 2025

Code System Code Type Description

MERCK INDEX

m8555

Created by admin on Mon Mar 31 18:05:08 GMT 2025 , Edited by admin on Mon Mar 31 18:05:08 GMT 2025

PRIMARY

Merck Index

RXCUI

72260

Created by admin on Mon Mar 31 18:05:08 GMT 2025 , Edited by admin on Mon Mar 31 18:05:08 GMT 2025

PRIMARY

RxNorm

SMS_ID

100000091602

Created by admin on Mon Mar 31 18:05:08 GMT 2025 , Edited by admin on Mon Mar 31 18:05:08 GMT 2025

PRIMARY

USAN

AA-67

Created by admin on Mon Mar 31 18:05:08 GMT 2025 , Edited by admin on Mon Mar 31 18:05:08 GMT 2025

PRIMARY

EPA CompTox

DTXSID1044198

Created by admin on Mon Mar 31 18:05:08 GMT 2025 , Edited by admin on Mon Mar 31 18:05:08 GMT 2025

PRIMARY

EVMPD

SUB03711MIG

Created by admin on Mon Mar 31 18:05:08 GMT 2025 , Edited by admin on Mon Mar 31 18:05:08 GMT 2025

PRIMARY

DRUG BANK

DB00790

Created by admin on Mon Mar 31 18:05:08 GMT 2025 , Edited by admin on Mon Mar 31 18:05:08 GMT 2025

PRIMARY

RS_ITEM_NUM

1510889

Created by admin on Mon Mar 31 18:05:08 GMT 2025 , Edited by admin on Mon Mar 31 18:05:08 GMT 2025

PRIMARY

CAS

107133-36-8

Created by admin on Mon Mar 31 18:05:08 GMT 2025 , Edited by admin on Mon Mar 31 18:05:08 GMT 2025

PRIMARY

NSC

758929

Created by admin on Mon Mar 31 18:05:08 GMT 2025 , Edited by admin on Mon Mar 31 18:05:08 GMT 2025

PRIMARY

PUBCHEM

441313

Created by admin on Mon Mar 31 18:05:08 GMT 2025 , Edited by admin on Mon Mar 31 18:05:08 GMT 2025

PRIMARY

CHEBI

8025

Created by admin on Mon Mar 31 18:05:08 GMT 2025 , Edited by admin on Mon Mar 31 18:05:08 GMT 2025

PRIMARY

ChEMBL

CHEMBL1581

Created by admin on Mon Mar 31 18:05:08 GMT 2025 , Edited by admin on Mon Mar 31 18:05:08 GMT 2025

PRIMARY

NCI_THESAURUS

C47666

Created by admin on Mon Mar 31 18:05:08 GMT 2025 , Edited by admin on Mon Mar 31 18:05:08 GMT 2025

PRIMARY

DAILYMED

1964X464OJ

Created by admin on Mon Mar 31 18:05:08 GMT 2025 , Edited by admin on Mon Mar 31 18:05:08 GMT 2025

PRIMARY

FDA UNII

1964X464OJ

Created by admin on Mon Mar 31 18:05:08 GMT 2025 , Edited by admin on Mon Mar 31 18:05:08 GMT 2025

PRIMARY

Related Record Type Details


					DV54578K4P

PERINDOPRIL ERBUMINE MONOHYDRATE

SOLVATE->ANHYDROUS


					91Z53KF68U

Erbumine

PARENT -> SALT/SOLVATE

Amount:


					1964X464OJ

PERINDOPRIL ERBUMINE

BASIS OF STRENGTH->SUBSTANCE

Interaction Type:

ASSAY (TITRATION)

Qualification:

EP

Amount:


					Y5GMK36KGY

PERINDOPRIL

PARENT -> SALT/SOLVATE

Related Record Type Details


					7X1W03173F

3-METHYLDECAHYDROPYRAZINO(1,2-A)INDOLE-1,4-DIONE, (3S,5AS,9AS,10AS)-

IMPURITY -> PARENT

Comments:

UNSPECIFIED

Qualification:

EP


					02OHD17721

PERINDOPRIL (2S,3AS,7AS)-OCTAHYDRO-2-CARBOXY-1H-INDOLE AMIDE

IMPURITY -> PARENT

Comments:

UNSPECIFIED

Qualification:

EP


					394F2XP06P

1-((2S)-2-((5RS)-3-CYCLOHEXYL-2,4-DIOXO-5-PROPYLIMIDAZOLIDIN-1-YL)PROPANOYL)OCTAHYDRO-1H-INDOLE-2-CARBOXYLIC ACID, (2S,3AS,7AS)-

IMPURITY -> PARENT

Comments:

UNSPECIFIED

Qualification:

EP


					3136GP4Z5Q

PERINDOPRILAT LACTAM A

IMPURITY -> PARENT

Comments:

UNSPECIFIED

Qualification:

EP


					PPJ3B822CZ

O-DESETHYL-O-METHYL PERINDOPRIL

IMPURITY -> PARENT

Comments:

UNSPECIFIED

Qualification:

EP


					413VL3U54U

2',7A-DI-EPI-PERINDOPRIL, (±)-

IMPURITY -> PARENT

Comments:

UNSPECIFIED

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP


					OQ0911H5P0

7A-EPI-PERINDOPRIL, (±)-

IMPURITY -> PARENT

Comments:

UNSPECIFIED

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP


					985WZS0TY0

1'',2-DI-EPI-PERINDOPRIL, (±)-

IMPURITY -> PARENT

Comments:

UNSPECIFIED

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP


					39K9H1X80S

3A,7A-DI-EPI-PERINDOPRIL, (±)-

IMPURITY -> PARENT

Comments:

UNSPECIFIED

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP


					534X2137QC

1'',3A-DI-EPI-PERINDOPRIL, (±)-

IMPURITY -> PARENT

Comments:

UNSPECIFIED

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP


					4N1VIR66DL

PERINDOPRIL DIKETOPIPERAZINE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					9ID44U804I

2-CARBOXYOCTAHYDROINDOLE, (2S,3AS,7AS)-

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (TLC)

Qualification:

EP

Amount:


					4WR9JW8F9B

2,7A-DI-EPI-PERINDOPRIL, (±)-

IMPURITY -> PARENT

Comments:

UNSPECIFIED

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP


					29N9292UAO

PERINDOPRILAT-DCC ACYLGUANIDINE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					7327NJ3271

1''-EPI-PERINDOPRIL, (±)-

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					AZ0CGX56BK

2',3A-DI-EPI-PERINDOPRIL, (±)-

IMPURITY -> PARENT

Comments:

UNSPECIFIED

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP


					AOC8B1C99O

3-CYCLOHEXYL-2-(((2S)-2-(((1S)-1-(ETHOXYCARBONYL)BUTYL)AMINO)PROPANOYL)AMINO)PROPANOIC ACID, (2S)-

IMPURITY -> PARENT

Comments:

UNSPECIFIED

Qualification:

EP


					51ANB778KK

1-ACETYLOCTAHYDRO-1H-INDOLE-2-CARBOXYLIC ACID, (2S,3AS,7AS)-

IMPURITY -> PARENT

Comments:

UNSPECIFIED

Qualification:

EP


					GR5K6963H1

2,3A-DI-EPI-PERINDOPRIL, (±)-

IMPURITY -> PARENT

Comments:

UNSPECIFIED

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP


					G458O7KI2W

PERINDOPRILAT LACTAM B

IMPURITY -> PARENT

Comments:

UNSPECIFIED

Qualification:

EP


					NYV8FIT0GU

1'',2'-DI-EPI-PERINDOPRIL, (±)-

IMPURITY -> PARENT

Comments:

UNSPECIFIED

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP


					2UV6ZNQ92K

PERINDOPRILAT

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					NCB86GKR6L

2,2'-DI-EPI-PERINDOPRIL, (±)-

IMPURITY -> PARENT

Comments:

UNSPECIFIED

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP


					3TMO3S0W85

1'',7A-DI-EPI-PERINDOPRIL, (±)-

IMPURITY -> PARENT

Comments:

UNSPECIFIED

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP


					PZ5ZXS76PJ

N-nitroso-perindopril

IMPURITY -> PARENT

Amount:


					0E0L880X1D

1-((2S)-2-AMINOPROPANOYL)OCTAHYDRO-1H-INDOLE-2-CARBOXYLIC ACID, (2S,3AS,7AS)-

IMPURITY -> PARENT

Comments:

UNSPECIFIED

Qualification:

EP


					KQK78CSH93

3A-EPI-PERINDOPRIL, (±)-

IMPURITY -> PARENT

Comments:

UNSPECIFIED

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP


					596MB5N22D

2-EPI-PERINDOPRIL, (±)-

IMPURITY -> PARENT

Comments:

UNSPECIFIED

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP


					716M4EVF1T

PERINDOPRILAT ISOPROPYL ESTER

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					LUF968K225

2'-EPI-PERINDOPRIL, (±)-

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Related Record Type Details


					2UV6ZNQ92K

PERINDOPRILAT

ACTIVE MOIETY

Details

SMILES

InChI

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Cmax

AUC

T1/2

Funbound

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Sourcing

PubMed

Patents

Sample Use Guides

C_max

T_1/2

F_unbound

Drug as perpetrator